T. brucei: The Parasite Causing African Sleeping Sickness

Trypanosoma brucei is a single-celled parasite transmitted by tsetse flies that causes human African trypanosomiasis, commonly known as sleeping sickness. The disease unfolds in two stages: an early phase of fever, headache, and joint pain while the parasite multiplies in the blood, and a late phase in which it invades the brain and progressively dismantles normal sleep-wake cycles. What makes T. brucei remarkable among pathogens is not just its lethality but its molecular ingenuity, particularly a surface-coat switching trick that has frustrated vaccine development for over a century.

Two Subspecies, Two Very Different Diseases

Sleeping sickness comes in two forms caused by two subspecies of T. brucei, and the distinction matters because they differ in geography, speed, animal reservoirs, and treatment. T. b. gambiense accounts for roughly 94% of reported cases and is found in West and Central Africa; it produces a chronic illness that can smolder for months or years before diagnosis. T. b. rhodesiense causes an acute, fast-moving infection across East and Southern Africa, often progressing to the brain-invasion stage within weeks.

The gambiense form is primarily a human-to-human cycle (with tsetse flies as the go-between), while rhodesiense is zoonotic, maintained in cattle and wild game, making it much harder to eliminate through human surveillance alone.² Both subspecies cause fever in nearly all patients, but some symptoms diverge in interesting ways. A review of infected travelers found that a trypanosomal chancre, a painful swelling at the bite site, appeared in about 84% of rhodesiense cases but only 47% of gambiense infections. Jaundice turned up in roughly a quarter of rhodesiense travelers, a finding that sometimes sent clinicians looking for liver disease rather than parasites.³

The same study highlighted a diagnostic trap. Among immigrants with long-standing gambiense infections, the dominant symptoms were often psychiatric and neurological: hallucinations, depression, motor deficits, and daytime drowsiness. Several patients had been admitted to psychiatric hospitals before anyone considered a parasitic cause.³

The Surface-Coat Shuffle

The reason there is no vaccine against sleeping sickness, and likely will not be one anytime soon, comes down to a single protein called variant surface glycoprotein (VSG). The parasite’s entire outer surface is coated with about ten million copies of one VSG type at a time. The host immune system eventually recognizes that coat and mounts an antibody attack, but before the population is wiped out, a small fraction of parasites have already switched to a different VSG. The genome of T. brucei contains over a thousand VSG genes, giving it an enormous wardrobe of disguises.

The switching itself happens through several mechanisms. Some switches are purely transcriptional: the parasite silences the active VSG gene and turns on a different one from among at least 17 expression sites identified in one well-studied lab strain.⁴ Others involve DNA rearrangements: a new VSG gene is physically copied into the active expression site by gene conversion. Research tracking this process in living mice found far more diversity within parasite populations than anyone had expected, along with evidence that the parasites can generate entirely new VSG variants by recombining fragments of different genes.⁵ This means the parasite is not simply cycling through a fixed deck of cards; it is generating new cards as it goes.

Telomere length, the repetitive DNA caps at the ends of chromosomes, influences which switching mechanism predominates. When telomeres at the active expression site were experimentally shortened, gene conversion jumped from about a quarter of switching events to 88%, and the overall switching rate went up. The interpretation is that short telomeres make the DNA at the active site fragile, triggering breaks that are repaired by copying in a new VSG gene.⁶

Stripping Away Antibodies in Real Time

Antigenic variation is the long game, but T. brucei also plays a short game against the immune system. Even after the host produces antibodies that bind to the current VSG coat, the parasite can physically clear those antibodies from its surface. As the parasite swims through the bloodstream, the drag of the surrounding fluid passively pushes antibody-VSG complexes toward the rear of the cell, where they are rapidly swallowed up through endocytosis.⁷ T. brucei has one of the highest known rates of endocytosis of any cell, and it funnels all of this activity through a tiny invagination at its base called the flagellar pocket.⁸ The result is that antibodies are internalized, recycled or destroyed, and the VSG coat is refreshed, all within minutes. The parasite essentially uses its own swimming motion as a built-in antibody removal system.

How T. brucei Enters the Brain

The transition from a manageable bloodstream infection to a lethal brain disease hinges on the parasite’s ability to cross the blood-brain barrier, the tightly sealed layer of cells lining the brain’s blood vessels. For T. b. gambiense, a key player in that crossing is an enzyme called brucipain, a cysteine protease the parasite releases. In laboratory experiments, brucipain triggered calcium signaling in human brain endothelial cells, and when the enzyme was chemically blocked, parasites could no longer cross the barrier.⁹ The downstream chain of events involves receptor activation that loosens the junctions between barrier cells, essentially forcing the gates open for the parasite to slip through.¹⁰

Once inside the central nervous system, the parasites provoke inflammation in brain structures that control the body’s internal clock. Despite its popular name, sleeping sickness is not really about sleeping too much. The hallmark is fragmented sleep: patients lose the normal separation between sleep and wakefulness, napping during the day and lying awake at night, rather than simply being drowsy all the time.¹¹ Mouse models of the infection show the same pattern, with disrupted circadian activity, sleep architecture, and body temperature rhythms mirroring what clinicians see in human patients.¹² Left untreated, the neurological decline progresses to confusion, personality changes, coma, and death.

Why Most Trypanosomes Cannot Infect Humans

Dozens of trypanosome species infect wild and domestic animals across sub-Saharan Africa, yet only two subspecies of T. brucei cause disease in people. The reason is a protein in human blood called apolipoprotein L1 (APOL1), which rides on HDL particles and is lethal to trypanosomes. When a trypanosome ingests APOL1 through normal feeding, the protein travels to the parasite’s lysosome, where the acidic environment activates it. It inserts into the lysosomal membrane, and when recycled back to the less acidic conditions of the parasite’s outer membrane, it opens ion-selective channels that flood the cell and kill it through osmotic swelling.¹³¹⁴

T. b. rhodesiense dodged this defense by evolving a protein called SRA (serum resistance-associated protein) that binds APOL1 inside the lysosome and neutralizes it. T. b. gambiense uses a different and less fully understood resistance strategy, but the end result is the same: these two subspecies slip past the defense that kills their relatives.

APOL1 Variants and the Evolutionary Arms Race

Human populations in West Africa fought back. Two naturally occurring APOL1 variants, called G1 and G2, restore the ability to kill even SRA-armed rhodesiense parasites. In both cases, the protein changes prevent SRA from binding effectively, echoing molecular signatures seen in Old World monkey versions of the gene.¹⁵ The G2 variant appears particularly potent: in an East African population, carrying a single copy was associated with about a fivefold reduced risk of rhodesiense infection.¹⁶

This protection comes at a cost. The same G1 and G2 variants are strongly linked to an elevated risk of chronic kidney disease, particularly among people of recent African descent. The mutations that improve parasite killing also make the APOL1 protein more hydrophobic and prone to damaging kidney filter cells called podocytes.¹⁷ It is a textbook example of evolutionary balancing: a gene variant that provides a major survival advantage against a deadly parasite was maintained in the population despite carrying a kidney disease penalty, much like the relationship between sickle-cell trait and malaria.

A Bizarre Approach to Gene Expression

T. brucei is not just unusual in how it evades immunity. Its basic molecular biology breaks rules that apply to nearly every other organism on Earth. Inside its single mitochondrion sits a structure called the kinetoplast, a massive network of interlocked circular DNA molecules. The genes encoded in this DNA are often incomplete as written; their messenger RNA transcripts must be extensively edited before they can produce functional proteins. The editing involves inserting and deleting uridine nucleotides, sometimes more than doubling the length of a transcript.¹⁸

The editing is directed by small guide RNA molecules and carried out by protein complexes called editosomes. Three distinct types of editosome have been identified, sharing a common core of 12 proteins but each carrying a unique endonuclease with different cutting preferences.¹⁹ Some genes can be edited in more than one way, producing alternative protein products from the same stretch of DNA. Editing patterns can vary between parasite cell lines, suggesting the system introduces a form of genetic diversity that compensates for the organism’s intolerance of conventional DNA mutations.¹⁸ Nothing quite like this system exists in animals, plants, or fungi. It has drawn sustained interest from molecular biologists because it represents an entirely different way of managing genetic information, and because disrupting it kills the parasite, making it a potential drug target.

Tsetse Flies and Vector Control

T. brucei is transmitted exclusively by tsetse flies of the genus Glossina, large biting flies found across sub-Saharan Africa. The parasite’s life cycle inside the fly is more flexible than researchers long assumed. Traditionally, it was thought that only a specific “stumpy” form of the parasite could survive in the fly gut, but experiments showed that even a single “slender” form, the rapidly dividing bloodstream stage, could establish a full infection in the fly and eventually reach the salivary glands, where parasites become infectious to the next mammalian host.²⁰ That finding complicates efforts to break transmission, because it means that even low-level bloodstream infections with mostly slender parasites can feed the fly-to-human cycle.

One factor influencing whether a tsetse fly picks up an infection is its gut microbiome. Flies that lack an obligate bacterial symbiont called Wigglesworthia are dramatically more susceptible to trypanosome colonization. The bacterium appears to be essential for the fly to develop a functioning immune response against the parasite, and without it, the fly’s defenses collapse.²¹

On the ground, vector control efforts have centered on insecticide-treated “tiny targets,” small panels of blue and black fabric impregnated with deltamethrin that attract and kill tsetse. These targets are far cheaper per unit area than traditional large traps, with modeling studies suggesting that deploying them at high density for just a few months per year could reduce fly populations by roughly 90%, enough to have a major impact on disease transmission.²² Field trials in Cameroon confirmed sharp initial reductions in tsetse density, though the same trials showed that fly populations partially rebounded after 12 months when targets were not maintained, underscoring the need for sustained deployment.²³

Diagnosis and the Staging Problem

Diagnosing sleeping sickness still relies heavily on finding the parasite under a microscope, either in blood smears or through concentration techniques that spin blood samples to concentrate trypanosomes. For gambiense disease, population-level screening campaigns use a rapid serological test to flag potential cases, with about 4.5 million people screened in 2021 and 2022 alone.²⁴

Once a case is confirmed, determining the disease stage is critical because it dictates treatment. Currently, staging requires a lumbar puncture to examine cerebrospinal fluid for parasites and elevated white blood cell counts. Stage 1 (hemolymphatic) patients can be treated with relatively straightforward drugs on-site, while stage 2 (meningoencephalitic) patients historically needed toxic intravenous medications administered in specialized facilities.²⁵ Researchers have looked for blood-based biomarkers that might replace the lumbar puncture, but results so far have been disappointing. A study testing neuron-specific enolase (NSE) as a plasma marker for rhodesiense staging found that while levels were higher in late-stage patients, the test was not reliable enough for clinical use, with a sensitivity of only about 69%.²⁶

From Arsenic to a Single Pill

The treatment landscape for sleeping sickness has been grim for most of its history. Melarsoprol, an arsenic-based drug introduced in 1949, was for decades the only option for late-stage disease and is still the sole treatment for late-stage rhodesiense infections. It is given intravenously, causes severe side effects, and kills a small percentage of patients outright through a toxic brain reaction. Both melarsoprol and pentamidine, the standard first-stage drug, enter the parasite through the same membrane transporter, and loss of a water-channel protein called aquaglyceroporin 2 has been linked to cross-resistance to both drugs.²⁷

The most significant therapeutic advance in years is acoziborole, a single oral pill that treats both stages of gambiense sleeping sickness. In a phase 2/3 trial, a single dose achieved treatment success in about 95% of late-stage patients at 18 months of follow-up. That success rate effectively eliminates the need for lumbar puncture staging, hospital admission, and days of intravenous infusion.²⁸ If regulatory approvals proceed, acoziborole could transform gambiense treatment from a logistical ordeal into something resembling a routine outpatient visit. Rhodesiense disease, however, still lacks any similarly convenient option.

The Livestock Toll

While sleeping sickness gets the headlines, the related animal disease called Nagana (African animal trypanosomiasis) arguably has a larger day-to-day economic impact across sub-Saharan Africa. Caused by several Trypanosoma species including T. brucei brucei (which does not infect humans because it remains susceptible to APOL1), Nagana saps the productivity of cattle, goats, and other livestock.²⁹ Infected cattle lose weight, produce less milk, and cannot work as draft animals. In one Ethiopian district, the overall cattle mortality attributed to trypanosomiasis was close to 9%, and the mean total economic loss per household reached about $1,200 per year, a devastating figure for smallholder farmers.³⁰ Farmers in affected areas often spend more money on trypanocidal drugs than on treatment for all other livestock diseases combined.³¹

Progress Toward Elimination

The global trajectory of sleeping sickness has been one of the more encouraging stories in neglected tropical disease control. Reported cases plummeted from peaks of tens of thousands in the late 1990s to 663 in 2020 and about 800 in each of the following two years.³²²⁴ The WHO’s target of fewer than 2,000 cases per year has been met. High-risk areas, defined as zones reporting more than one case per 10,000 people annually, shrank by 90% between the early 2000s and recent assessments, and only about 3,000 square kilometers remain classified as very high or high risk.²⁴

Getting from elimination as a public health problem to zero transmission is a different challenge. Gambiense disease depends on finding every last asymptomatic carrier in remote rural areas. Rhodesiense disease hides in animal reservoirs that surveillance campaigns cannot screen. Political instability in endemic countries can collapse control programs overnight, and history suggests that the disease resurges whenever attention lapses. The tools, from tiny targets to single-dose oral drugs, are better than they have ever been. Whether the political will and funding to finish the job will hold is the open question.

1
PubMed Central. Human African Trypanosomiasis (Sleeping Sickness)-Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Prevention
2
Wiley Online Library (Clinical Microbiology and Infection). Sleeping sickness
3
PLoS Neglected Tropical Diseases. Sleeping Sickness in Travelers – Do They Really Sleep?
4
PubMed Central. VSG switching in Trypanosoma brucei: antigenic variation analysed using RNAi in the absence of immune selection
5
PubMed Central. The in vivo dynamics of antigenic variation in Trypanosoma brucei
6
PLOS Pathogens. Telomere Length Affects the Frequency and Mechanism of Antigenic Variation in Trypanosoma brucei
7
PubMed. Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes
8
PubMed Central. The endocytic activity of the flagellar pocket in Trypanosoma brucei is regulated by an adjacent phosphatidylinositol phosphate kinase
9
PubMed Central. Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease
10
PLoS Neglected Tropical Diseases. Protease Activated Receptor Signaling Is Required for African Trypanosome Traversal of Human Brain Microvascular Endothelial Cells
11
PubMed. Why trypanosomes cause sleeping sickness
12
Nature Communications. Sleeping sickness is a circadian disorder
13
PubMed. Apolipoprotein L-I is the trypanosome lytic factor of human serum
14
PubMed Central. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis
15
PubMed Central. Evolution of the primate trypanolytic factor APOL1
16
PubMed Central. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis
17
PubMed Central. Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease
18
Nucleic Acids Research. Cell-line specific RNA editing patterns in Trypanosoma brucei suggest a unique mechanism to generate protein variation in a system intolerant to genetic mutations
19
PubMed Central. The Architecture of Trypanosoma brucei editosomes
20
eLife. Unexpected plasticity in the life cycle of Trypanosoma brucei
21
PLOS Pathogens. Trypanosome Infection Establishment in the Tsetse Fly Gut Is Influenced by Microbiome-Regulated Host Immune Barriers
22
PLOS Neglected Tropical Diseases. Optimal Strategies for Controlling Riverine Tsetse Flies Using Targets: A Modelling Study
23
PLoS Neglected Tropical Diseases. Impact of a small-scale tsetse fly control operation with deltamethrin impregnated “Tiny Targets” on tsetse density and trypanosomes’ circulation in the Campo sleeping sickness focus of South Cameroon
24
PubMed Central. The elimination of human African trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets
25
PubMed Central. The detection and treatment of human African trypanosomiasis
26
PubMed Central. Plasma Neuron-Specific Enolase is not a reliable biomarker for staging Trypanosoma brucei rhodesiense sleeping sickness patients
27
PubMed Central. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story
28
PubMed Central. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense
29
Combating and Controlling Nagana and Tick-Borne Diseases in Livestock. Epidemiology and Economic Importance of African Animal Trypanosomiasis
30
PubMed Central. Epidemiology and economic impact of bovine trypanosomosis in Jawi District, Northwest Ethiopia
31
PubMed Central. Epidemiology and Economic Cost of Trypanosomosis Among SmallHolder Cattle Herders in Arba Minch and Zuria Districts, Gamo Zone, Ethiopia
32
PLoS Neglected Tropical Diseases. The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020